Boston Scientific annual cash and equivalents
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Boston Scientific Cash & Equivalents Growth & History (BSX)
Boston Scientific's cash and equivalents was $1.97B for fiscal 2025.
View full Boston Scientific company overviewBoston Scientific annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.97B | $1.55B | +374.64% |
| 2024 | 2024-12-31 | $414.0M | −$451.0M | −52.14% |
| 2023 | 2023-12-31 | $865.0M | −$63.0M | −6.79% |
| 2022 | 2022-12-31 | $928.0M | −$997.0M | −51.79% |
| 2021 | 2021-12-31 | $1.93B | $191.0M | +11.01% |
| 2020 | 2020-12-31 | $1.73B | $1.52B | +699.08% |
| 2019 | 2019-12-31 | $217.0M | $71.0M | +48.63% |
| 2018 | 2018-12-31 | $146.0M | −$42.0M | −22.34% |
| 2017 | 2017-12-31 | $188.0M | −$8.0M | −4.08% |
| 2016 | 2016-12-31 | $196.0M | −$123.0M | −38.56% |
| 2015 | 2015-12-31 | $319.0M | −$268.0M | −45.66% |
| 2014 | 2014-12-31 | $587.0M | $370.0M | +170.51% |
| 2013 | 2013-12-31 | $217.0M | $10.0M | +4.83% |
| 2012 | 2012-12-31 | $207.0M | −$60.0M | −22.47% |
| 2011 | 2011-12-31 | $267.0M | $54.0M | +25.35% |
| 2010 | 2010-12-31 | $213.0M | −$651.0M | −75.35% |
| 2009 | 2009-12-31 | $864.0M | −$777.0M | −47.35% |
| 2008 | 2008-12-31 | $1.64B | $189.0M | +13.02% |
| 2007 | 2007-12-31 | $1.45B | — | — |
Boston Scientific quarterly cash and equivalents
Q4.08
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $539.0M | $5.0M | +0.94% |
| Q1 2026 | 2026-03-31 | $1.45B | $728.0M | +100.41% |
| Q4 2025 | 2025-12-31 | $1.97B | $1.55B | +374.64% |
| Q3 2025 | 2025-09-30 | $1.27B | −$1.23B | −49.04% |
| Q2 2025 | 2025-06-30 | $534.0M | −$2.38B | −81.67% |
| Q1 2025 | 2025-03-31 | $725.0M | −$1.60B | −68.87% |
| Q4 2024 | 2024-12-31 | $414.0M | −$451.0M | −52.14% |
| Q3 2024 | 2024-09-30 | $2.50B | $1.55B | +162.82% |
| Q2 2024 | 2024-06-30 | $2.91B | $2.49B | +583.80% |
| Q1 2024 | 2024-03-31 | $2.33B | $1.76B | +308.60% |
| Q4 2023 | 2023-12-31 | $865.0M | −$63.0M | −6.79% |
| Q3 2023 | 2023-09-30 | $952.0M | $614.0M | +181.66% |
| Q2 2023 | 2023-06-30 | $426.0M | $150.0M | +54.35% |
| Q1 2023 | 2023-03-31 | $570.0M | $245.0M | +75.38% |
| Q4 2022 | 2022-12-31 | $928.0M | −$997.0M | −51.79% |
| Q3 2022 | 2022-09-30 | $338.0M | −$1.61B | −82.64% |
| Q2 2022 | 2022-06-30 | $276.0M | −$2.40B | −89.68% |
| Q1 2022 | 2022-03-31 | $325.0M | −$1.69B | −83.88% |
| Q4 2021 | 2021-12-31 | $1.93B | $191.0M | +11.01% |
| Q3 2021 | 2021-09-30 | $1.95B | −$75.0M | −3.71% |
| Q2 2021 | 2021-06-30 | $2.67B | $951.0M | +55.16% |
| Q1 2021 | 2021-03-31 | $2.02B | $1.65B | +444.86% |
| Q4 2020 | 2020-12-31 | $1.73B | $1.52B | +699.08% |
| Q3 2020 | 2020-09-30 | $2.02B | $1.75B | +629.96% |
| Q2 2020 | 2020-06-30 | $1.72B | $1.60B | +1301.63% |
| Q1 2020 | 2020-03-31 | $370.0M | $231.0M | +166.19% |
| Q4 2019 | 2019-12-31 | $217.0M | $71.0M | +48.63% |
| Q3 2019 | 2019-09-30 | $277.0M | $109.0M | +64.88% |
| Q2 2019 | 2019-06-30 | $123.0M | −$85.0M | −40.87% |
| Q1 2019 | 2019-03-31 | $139.0M | −$148.0M | −51.57% |
| Q4 2018 | 2018-12-31 | $146.0M | −$42.0M | −22.34% |
| Q3 2018 | 2018-09-30 | $168.0M | −$42.0M | −20.00% |
| Q2 2018 | 2018-06-30 | $208.0M | $13.0M | +6.67% |
| Q1 2018 | 2018-03-31 | $287.0M | $131.0M | +83.97% |
| Q4 2017 | 2017-12-31 | $188.0M | −$8.0M | −4.08% |
| Q3 2017 | 2017-09-30 | $210.0M | −$27.0M | −11.39% |
| Q2 2017 | 2017-06-30 | $195.0M | −$243.0M | −55.48% |
| Q1 2017 | 2017-03-31 | $156.0M | −$182.0M | −53.85% |
| Q4 2016 | 2016-12-31 | $196.0M | −$123.0M | −38.56% |
| Q3 2016 | 2016-09-30 | $237.0M | −$113.0M | −32.29% |
| Q2 2016 | 2016-06-30 | $438.0M | −$465.0M | −51.50% |
| Q1 2016 | 2016-03-31 | $338.0M | $96.0M | +39.67% |
| Q4 2015 | 2015-12-31 | $319.0M | −$268.0M | −45.66% |
| Q3 2015 | 2015-09-30 | $350.0M | $104.0M | +42.28% |
| Q2 2015 | 2015-06-30 | $903.0M | $546.0M | +152.94% |
| Q1 2015 | 2015-03-31 | $242.0M | $51.0M | +26.70% |
| Q4 2014 | 2014-12-31 | $587.0M | $370.0M | +170.51% |
| Q3 2014 | 2014-09-30 | $246.0M | −$325.0M | −56.92% |
| Q2 2014 | 2014-06-30 | $357.0M | −$173.0M | −32.64% |
| Q1 2014 | 2014-03-31 | $191.0M | −$77.0M | −28.73% |
| Q4 2013 | 2013-12-31 | $217.0M | $10.0M | +4.83% |
| Q3 2013 | 2013-09-30 | $571.0M | $219.0M | +62.22% |
| Q2 2013 | 2013-06-30 | $530.0M | $159.0M | +42.86% |
| Q1 2013 | 2013-03-31 | $268.0M | −$16.0M | −5.63% |
| Q4 2012 | 2012-12-31 | $207.0M | −$60.0M | −22.47% |
| Q3 2012 | 2012-09-30 | $352.0M | $76.0M | +27.54% |
| Q2 2012 | 2012-06-30 | $371.0M | $217.0M | +140.91% |
| Q1 2012 | 2012-03-31 | $284.0M | −$311.0M | −52.27% |
| Q4 2011 | 2011-12-31 | $267.0M | $54.0M | +25.35% |
| Q3 2011 | 2011-09-30 | $276.0M | −$348.0M | −55.77% |
| Q2 2011 | 2011-06-30 | $154.0M | −$657.0M | −81.01% |
| Q1 2011 | 2011-03-31 | $595.0M | $76.0M | +14.64% |
| Q4 2010 | 2010-12-31 | $213.0M | −$651.0M | −75.35% |
| Q3 2010 | 2010-09-30 | $624.0M | −$757.0M | −54.82% |
| Q2 2010 | 2010-06-30 | $811.0M | −$383.0M | −32.08% |
| Q1 2010 | 2010-03-31 | $519.0M | — | — |
| Q4 2009 | 2009-12-31 | $864.0M | −$777.0M | −47.35% |
| Q3 2009 | 2009-09-30 | $1.38B | — | — |
| Q2 2009 | 2009-06-30 | $1.19B | — | — |
| Q4 2008 | 2008-12-31 | $1.64B | — | — |
Boston Scientific cash and equivalents trends
Over the last five fiscal years, Boston Scientific's cash and equivalents increased from $1.73B to $1.97B, a change of $231.0M. The latest reported quarter, Q2 2026, shows $539.0M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Boston Scientific source filings ↗